In clinical methodology, assay sensitivity refers to the ability of a study to distinguish an effective treatment from a less effective or ineffective treatment. It is a term defined in ICH E10 and must not be confused with the analytical sensitivity of a laboratory procedure. In non-inferiority studies, it determines whether a finding of non-inferiority can be interpreted as evidence of efficacy at all.<\/p>\n
Assay sensitivity is a property of the entire clinical trial. It arises from an appropriate control group, a meaningful endpoint, a comparable patient population, and conduct that does not obscure differences. In a superiority study, a lack of assay sensitivity typically results in a failure to demonstrate efficacy. In a non-inferiority study, however, it can lead to the misleading result that an ineffective treatment appears non-inferior.<\/p>\n
For an active-controlled study without a placebo, ICH E10 requires two logical steps. First, earlier similarly designed studies must show that the active control was reliably able to distinguish effective from less effective or ineffective treatments. Second, the current study must be conducted in such a way that this ability was not lost. Historical evidence and contemporary study quality thus work together.<\/p>\n
A successful non-inferiority test usually contains no direct evidence of assay sensitivity. Its conclusion is based on the assumption that the active control would continue to have a reliable effect compared to placebo under the current conditions. The choice of the non-inferiority margin must therefore be supported by historical efficacy data and clinical considerations; it must not be larger than the smallest reliably expected effect of the control.<\/p>\n
Deviations in inclusion criteria, concomitant therapy, control dosage, endpoint, or observation period can weaken the historical reference. Poor adherence, numerous losses to follow-up, a spontaneously improving population, or imprecise diagnostic criteria also reduce the ability to show differences. A three-arm design with investigational treatment, active control, and placebo can provide direct evidence of assay sensitivity by comparing the active control with the placebo.<\/p>\n
In the terminology of thorough QT\/QTc studies, ICH E14 uses assay sensitivity to refer to the demonstrated ability to detect a clinically relevant QT\/QTc prolongation. A concurrent positive control with a mean effect of approximately 5 milliseconds can demonstrate this ability. Thus, in both cases, the shared term refers to the detectability of a real effect, but relates to different study questions and methods of proof.<\/p>\n
It does not refer to analytical sensitivity, such as the lowest concentration that a bioanalytical assay can reliably measure. This is a property of a measurement method. Assay sensitivity according to ICH E10, by contrast, is a property of the study design and its execution. The connection to existing entries for non-inferiority studies lies precisely in this methodological prerequisite.<\/p>\n
Assay sensitivity becomes particularly critical when the chosen disease or endpoint exhibits highly variable courses. High placebo responses or spontaneous improvement can make effective and ineffective treatments appear similar. Historical evidence must therefore precisely cover the planned indication, dose, endpoint definition, and study duration; a general proof of efficacy for the active control is not sufficient.<\/p>\n
Study quality here is not merely an operational requirement. Protocol violations, low adherence, or missing endpoint data can directly destroy the methodological validity because they shift group differences toward equality. The retrospective examination of the population actually enrolled and the concomitant treatments used is therefore part of the interpretation of a non-inferiority result.<\/p>\n
Before starting a non-inferiority study, historical control studies, selection criteria, endpoint definition, treatment regimens, and the margin must methodologically align. During execution, treatment adherence, concomitant medication, dropouts, and the quality of endpoint assessment are particularly relevant, as they can mask differences between groups. A result that is merely statistically non-inferior is not enough if the ability to distinguish remains doubtful.<\/p>\n
Full-service CROs like Mediconomics support planning through literature and data review of historical efficacy, the definition of verifiable endpoints, and quality control of critical study steps. Biostatistics, Clinical Operations, and Medical Writing can methodologically justify assay sensitivity in the study protocol, Statistical Analysis Plan, and clinical study report.<\/p>\n
Is assay sensitivity the same as statistical power?<\/strong><\/p>\n The concepts are different. Power describes the probability of detecting a difference under certain assumptions; assay sensitivity additionally encompasses the actual ability of the design and execution to separate effective from ineffective treatments.<\/p>\n Why is a lack of assay sensitivity particularly problematic in non-inferiority?<\/strong><\/p>\n Because an ineffective investigational treatment can falsely appear non-inferior to an active control that is also not distinguishably effective.<\/p>\n Can a positive control prove assay sensitivity?<\/strong><\/p>\n In a QT\/QTc study, yes, if it shows the expected effect; in a non-inferiority study, a placebo comparison of the active control can provide this evidence.<\/p>\n In clinical methodology, assay sensitivity refers to the ability of a study to distinguish an effective treatment from a less effective or ineffective treatment. It is a term defined in ICH E10 and must not be confused with the analytical sensitivity of a laboratory procedure. In non-inferiority studies, it determines whether a finding of non-inferiority […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[27],"class_list":["post-8034","glossary","type-glossary","status-publish","hentry","glossary-cat-nichtklinik-pharmakologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8034\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8034"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n